Tepezza (Teprotumumab-trbw) A Groundbreaking Treatment for Thyroid Eye Disease

Tepezza (Teprotumumab-trbw): A Groundbreaking Treatment for Thyroid Eye Disease

Thyroid Eye Disease (TED) is a rare autoimmune condition that affects the eyes, causing inflammation and swelling in the tissues surrounding them. The condition can cause significant discomfort, visual disturbances, and in severe cases, lead to blindness. Until recently, there were limited treatment options available for patients with TED, but the approval of Tepezza (Teprotumumab-trbw) by the U.S. Food and Drug Administration (FDA) in 2020 has changed the game for patients with this debilitating disease.

Tepezza is a monoclonal antibody designed to target and reduce the inflammation seen in TED. It works by binding to insulin-like growth factor-1 receptor (IGF-1R), a protein that is over-expressed on the cells that cause inflammation in TED. By blocking the activity of this protein, Tepezza can reduce the inflammation and swelling that cause the symptoms of TED.

Clinical trials of Tepezza have shown impressive results, with patients experiencing significant improvements in symptoms such as eye bulging, tearing, double vision, and pain. In a study of 88 patients with active TED, 82.9% of those who received Tepezza showed a reduction in eye bulging, compared to only 9.5% of those who received a placebo. Other symptoms such as pain, inflammation, and redness also improved significantly in patients receiving Tepezza.

Another significant benefit of Tepezza is that the improvements in symptoms are long-lasting. In a follow-up study, patients who received Tepezza showed sustained improvements in symptoms for up to one year after the end of treatment. This means that patients may require fewer follow-up treatments, which can reduce the overall burden of treatment.

Tepezza is delivered via intravenous infusion over a period of several months. While the treatment can be expensive, with an average cost of around $14,000 per vial, it can be a life-changing option for patients with TED. Most insurance plans will cover the cost of treatment, including Medicare and private insurance.

There are some potential side effects of Tepezza, including muscle weakness, nausea, and diarrhea, although these are generally mild and well-tolerated. Patients receiving Tepezza are typically monitored closely for any adverse reactions, and the majority of patients do well with treatment.

In summary, Tepezza is a groundbreaking new treatment for Thyroid Eye Disease that offers significant benefits for patients suffering from this rare condition. With the ability to target and reduce the inflammation that drives symptoms in TED, Tepezza can improve quality of life for patients and lead to long-lasting improvements in symptoms. While the cost of treatment can be high, most insurance plans will cover the cost, making this an accessible option for many. If you or someone you know is affected by TED, Tepezza may be worth discussing with your doctor as a treatment option.